Villagracia, Ronald P.
HRN: 26-68-62 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/23/2025
CO-AMOXICLAV 625MG (TAB)
02/23/2025
03/01/2025
ORAL
625mg
Q8
SP Open Cystolithotomy
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes